

Sales Through Retail Pharmacies (Twelve months to September 2008*)

NORTH AMERICA \$225.4 billion up 2%

U.S.A. \$208.1 billion up 1%
CANADA \$17.2 billion up 7%

EUROPE (TOP 5) \$117.3 billion up 3%

GERMANY \$35.9 billion up 5%
FRANCE \$31.4 billion up 2%
UK \$16.7 billion down 2%
ITALY \$17.6 billion up 2%
SPAIN \$15.6 billion up 6%

JAPAN (including hospitals) \$65.4 billion up 4%

LATIN AMERICA (TOP 3) \$24.8 billion up 10%

BRAZIL \$12.7 billion up 12%
MEXICO \$8.9 billion up 4%
ARGENTINA \$3.1 billion up 22%

AUSTRALIA/NZ \$8.2 billion up 11%

The top 5 therapy classes at ATC3 level in the 12 months to September 2008 were:

1. C10A – Cholesterol & trigly. regulators
2. A2B - Antiulcerants
3. N6A – Antidepressants & mood stabilisers
4. N5A - Antipsychotics
5. N3A – Anti-epileptics

The top 5 products in the 12 months to September 2008 were:

1. Lipitor
2. Plavix
3. Nexium
4. Seretide/Advair
5. Enbrel

The top 5 corporations in the 12 months to September 2008 were:

1. Pfizer
2. GlaxoSmithKline
3. Novartis
4. AstraZeneca
5. Sanofi-Aventis